Physician profile
Ryan M Ford
NPI 1235166612
$19,952.73
in general payments reported to CMS, 2019-2025
8 companies · $3,007 in 2025
The $3,007 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,012 · 2021: $2,970 · 2022: $4,690 · 2023: $1,105 · 2024: $3,169 · 2025: $3,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,045 · Honoraria: $3,000 · Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,045.00 |
| Honoraria | $3,000.00 |
| Food and Beverage | $1,236.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12,427.83 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $3,685.00 | 2021-2023 | |
| Orphalan INC | $3,025.03 | 2024-2025 | Cuvrior |
| Mirum Pharmaceuticals, INC. | $519.05 | 2025 | Livmarli |
| Madrigal Pharmaceuticals | $265.72 | 2024-2025 | Resmetirom, Rezdiffra |
| Intercept Pharmaceuticals, INC. | $15.19 | 2024 | |
| Eton Pharmaceuticals, INC. | $14.91 | 2025 | Galzin, Carglumic Acid, Nitisinone |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.